NorthWest Biotherapeutics Inc (NWBO)

[CherryTree1]

Some more on NWBO patent protection and other protects afforded NWBO.

Yes, other forms of legal protection beyond standard patents may prevent competitors from using Northwest Biotherapeutics' (NWBO) DCVax technology, primarily through regulatory exclusivity and potentially trade secrets.
Regulatory Exclusivity
Regulatory exclusivity is a separate form of protection granted by government regulatory bodies like the FDA in the U.S. or the EMA in Europe, provided specific criteria are met. It bars competitors from obtaining marketing approval for the same drug for a set period, regardless of patent status.
Orphan Drug Exclusivity (ODE): This is a key potential protection for DCVax-L, which is used for brain cancer (glioblastoma multiforme), a rare disease. If the drug receives FDA approval with an Orphan Drug Designation, it is generally entitled to a seven-year market exclusivity period in the U.S.. In Europe, this period is typically ten years.
Data Exclusivity: Regulatory authorities require the original applicant to submit extensive data from preclinical and clinical trials. Data exclusivity prevents subsequent applicants from relying on this data to support their own marketing applications for a specified period (e.g., five years for a new chemical entity in the U.S.), forcing them to conduct their own expensive and time-consuming trials.
Trade Secrets
NWBO may also protect certain aspects of its technology, such as specific manufacturing processes (like the Flaskworks system for a closed manufacturing process), as trade secrets. Unlike patents, which require public disclosure of the invention, trade secrets rely on keeping information confidential. This protection can theoretically last indefinitely as long as the information remains secret and reasonable efforts are made to maintain its confidentiality.
In summary, NWBO employs an integrated strategy for intellectual property protection that combines a substantial patent portfolio with other mechanisms, such as seeking Orphan Drug status, to protect its technology from competitors.

And in additions:

Yes, Northwest Biotherapeutics' (NWBO) DCVax technology is protected by a portfolio of patents. These patents cover various aspects, including manufacturing processes, the composition of the therapy, and methods of use.
The duration of protection varies by individual patent, but generally, a U.S. utility patent provides exclusive rights for 20 years from its filing date.
Key details regarding NWBO's patent portfolio:
Multiple Patents: NWBO has an integrated strategy involving numerous issued patents and many more pending in the U.S. and internationally.
Broad Coverage: The patents cover the use of dendritic cells in specific DCVax products, unique manufacturing processes (including automation), and methods for producing more potent dendritic cells.
Recent Additions: In June 2024, NWBO announced an exclusive license for an additional portfolio of dendritic cell technologies, which includes five new patent families filed in 2023. These newly filed patents have their full potential patent life ahead of them (up to 2043).
Patent Expirations: Specific patent expiration dates vary. For example, one patent mentioned in a third-party analysis (US8673893) has an expiration date in July 2028, but this is only one of many patents in their portfolio. The company has consistently asserted its "freedom to operate" regarding other parties' patents.
The company actively manages its intellectual property to ensure robust protection and the ability to scale up manufacturing of its DCVax products.

People complain about Linda Powers being a lawyer but in these matters it comes in quite handy